Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder was president of SiROP Global, a web-based technology that connects universities in Europe and worldwide. While managing SiROP, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Protein (DARPins) as specific protein inhibitors. He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Blueprint Medicines, SiROP Global, and is a board observer at Tracon Pharmaceuticals. He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.